Management of asthma and copd therapeutics yr 5 2010 11a

21
Year 4 Medical Pharmacology Therapeutic

Transcript of Management of asthma and copd therapeutics yr 5 2010 11a

Page 1: Management of asthma and copd therapeutics yr 5 2010 11a

Year 4 Medical Pharmacology Therapeutic

Page 2: Management of asthma and copd therapeutics yr 5 2010 11a

Case 1ABC, a 16-year old girl presented with difficulty in breathing and coughing progressively worsened over the past 2 days◦ Symptoms preceded by sore throat, rhinorrhoea

and cough for 3 days

◦ History of cough on and off, went to GP and was given cough medication.

On examination◦ Dyspnoeic, wheezing+, able to speak in short

sentences

◦ BP 110/83 mmHg, PR 130/min, T- 37.8oC

◦ hyperinflated chest, intercostal recession+ Rhonci++ with decreased breath sound on the left side

Page 3: Management of asthma and copd therapeutics yr 5 2010 11a

Diagnosis?

◦ Acute exacerbation of bronchial asthma

Further history to ask?

◦ Recurrent night cough

◦ Family history of asthma

How do you assess asthma severity?

In your opinion how is her condition?

Page 4: Management of asthma and copd therapeutics yr 5 2010 11a

What is the drug of choice and why?

◦ Β2- receptor agonist (short acting)

◦ For fast relief

Why not use other bronchodilators such as aminophylline or ipratropium?

◦ Aminophylline is not as efficacious as SABA and has more risk for serious adverse effects than SABA

◦ Ipratropium is not as efficacious as SABA

What is the preferred route of administration?

◦ Nebulizer

◦ Combination with ipratroprium improve pulmonary function and reduce rate of hospitalization

Page 5: Management of asthma and copd therapeutics yr 5 2010 11a

Any role of corticosteroids?

◦ Antiinflammatory.

◦ Block the reaction to allergen and reduce airway hyperresponsiveness.

◦ Inhibit cytokine production, adhesion protein activation and inflammatory cell migration and activation.

◦ Reverse β2 receptor downregulation.

◦ Inhibit microvascular leakage

What is the mode of administration for the patient?

◦ Oral vs parenteral

Page 6: Management of asthma and copd therapeutics yr 5 2010 11a

ABC responded well to treatment. She was discharged after 3 days in the ward

What advice you would give ABC before discharge?

What type of medication would you prescribe to ABC and why

SABA?

Corticosteroid inhaler?

Continue oral prednisolone for 5-7 days then off

Review?

Page 7: Management of asthma and copd therapeutics yr 5 2010 11a

Case 2

XYZ, a 45-year old man with a long history of persistent asthma went to A&E with complaint of severe SOB and wheezing.

Able to speak two or three words without taking a breath.

On inhaler beclomethasone 4 puff (80mcg/puff) bd, salbutamol prn.

Ran out of beclomethasone 1 week ago, been taking salbutamol only with increasing frequency upto every 3 hours on the day of admission

Page 8: Management of asthma and copd therapeutics yr 5 2010 11a

Case 2

On examination HR 130/min RR 30/min BP 130/90mmHG ABG under room air

◦ pH 7.4 (N 7.35-7.45)◦ PaO2 55mmHg (>80 mmHg)◦ PaCO2 40 mmHg (35-45 mmHg)

Comment the ABG results – normal or not normal??

Page 9: Management of asthma and copd therapeutics yr 5 2010 11a

Mild

pH

PaO2

PaCO2

HCO3-

Moderate

pH

PaO2

PaCO2

HCO3-

Severe*

pH

PaO2

PaCO2

HCO3-

* Beware the following:

• Speechless patient

• PEFR <50%

• Resp Rate >25

• Tachycardia >110 (pre 2 agonist)

ABG in Acute ASTHMA

Page 10: Management of asthma and copd therapeutics yr 5 2010 11a

Case 2ECG showed sinus tachycardia with

occasional premature ventricular contractions.

XYZ was given SC 0.5mg terbutaline with minimal improvement, O2 at 4L/min by nasal cannula.

Another SC 0.5mg terbutaline was then given. Subsequently his HR 145/min and he complained of palpitations and shakiness.

ABG pH 7.39, PaO2 60mmHg, PaCo2 42 mmHg

Page 11: Management of asthma and copd therapeutics yr 5 2010 11a

Summary of lab resuts Before terbutaline ABG

◦ pH 7.4◦ PaO2 55 mmHg◦ PaCO2 40 mmHg

BUSE◦ Na 140 mEq/L◦ K 4.1 mEq/L◦ Cl 105 mEq/L

After 2nd terbutaline ABG

◦ pH 7.39◦ PaO2 60◦ PaCO2 42

BUSE◦ Na 138◦ K 3.5

What adverse effects experienced by XYZ are consistent with systemic β2 agonist administration?

Page 12: Management of asthma and copd therapeutics yr 5 2010 11a

Case 2 ECG showed sinus tachycardia with

occasional premature ventricular contractions.

XYZ was given SC 0.5mg terbutaline with minimal improvement, O2 at 4L/min by nasal cannula.

Another SC 0.5mg terbutaline was then given. Subsequently his HR 145/min and he complained of palpitations and shakiness.

ABG pH 7.39, PaO2 60mmHg, PaCo2 42 mmHg

Β2 agonist are cardiac stimulants that may cause tachycardia and rarely arrhythmias

Page 13: Management of asthma and copd therapeutics yr 5 2010 11a

Summary of lab resuts Before terbutaline ABG

◦ pH 7.4◦ PaO2 55 mmHg◦ PaCO2 40 mmHg

BUSE◦ Na 140 mEq/L◦ K 4.1 mEq/L◦ Cl 105 mEq/L

After 2nd terbutaline ABG

◦ pH 7.39◦ PaO2 60◦ PaCO2 42

BUSE◦ Na 138◦ K 3.5

Decrease could be due to β2 adrenergic activation of Na+ K+ pump and subsequent transport of K intracellularly.

At usual doses, inhaler salbutamol or terbutaline cause relatively little effects on K, effect more noticeable with systemic administration.

Page 14: Management of asthma and copd therapeutics yr 5 2010 11a

That’s all,

Thank you

Page 15: Management of asthma and copd therapeutics yr 5 2010 11a
Page 16: Management of asthma and copd therapeutics yr 5 2010 11a
Page 17: Management of asthma and copd therapeutics yr 5 2010 11a
Page 18: Management of asthma and copd therapeutics yr 5 2010 11a
Page 19: Management of asthma and copd therapeutics yr 5 2010 11a
Page 20: Management of asthma and copd therapeutics yr 5 2010 11a

ASTHMA DRUGS

Bronchodilatation

↓ Inflammation

ß2 receptor Agonist

Salbutamol

MethylxanthinesTheophylline,aminophylline

AnticholinergicsIpratropium bromide

Mast cell stabilizersodium cromoglycate

CorticosteroidsBeclomethasone,

budesonide

Leukotriene pathway inhibitors

montelukast

Anti-IgE monoclonalAntibodiesomalizumab

Page 21: Management of asthma and copd therapeutics yr 5 2010 11a

Short acting ß2 agonists

Inhaled corticosteroidsCromoglycates

TheophyllineLeukotriene antagonists

Long acting ß2 agonists

Oral steroids

severity

reliever

preventer

controller